From: Characterization of lung stem cell niches in a mouse model of bleomycin-induced fibrosis
A. Number of cells in BALF after a week of bleomycin treatment | ||||||||
---|---|---|---|---|---|---|---|---|
 | WT saline (day 7) | WT bleomycin (day 7) | NOX saline (d7) | NOX bleomycin (day 7) | DKO saline (day 7) | DKO bleomycin (day 7) | ||
Total cell count (×105/ml) | 4.27 ± 0.184 | 28.3 ± 0.224 | 4.515 ± 0.223 | 48.91* ± 1.59 | 2.61 ± 0.16 | 8.42 ± 0.13 | ||
Macrophages (×10 5 /ml) | 4.16 ± 0.57 (97.2%) | 11.14 ± 4.08 (37.6%) | 4.01 ± 0.31 (89.9%) | 28.14* ± 6.83 (57.47%) | 1.87 ± 0.64 (71.64%) | 4.19 ± 3.18 (49.82%) | ||
Lymphocytes (×10 5 /ml) | 0.08 ± 0.01 (2.0%) | 12.63 ± 2.49 (46.0%) | 0.09 ± 0.02 (2.01%) | 16.91* ± 3.65 (34.53%) | 1.2 ± 0.01 (4.59%) | 1.44 ± 0.66 (17.12%) | ||
Neutrophils (×10 5 /ml) | 0.03 ± 0.01 (0.7%) | 4.5 ± 0.97 (16.3%) | 0.11 ± 0.01 (0.02%) | 3.91 ± 0.53 (7.98%) | 0.63 ± 0.14 (24.13%) | 2.78 ± 1.06 (33%) | ||
B. Number of CD45 + cells in BALf before and after Bleomycin treatment | ||||||||
BALf | Â | Â | Â | Â | Â | Â | Â | Â |
10 5 /ml | WS | WB7 | WB14 | WB21 | NOXS | NOXB21 | DKOS | DKOB21 |
Total cells | 4.27 ± 0.18 | 28.3 ± 0.22 | 10.32 ± 2.74 | 9.32 ± 1.74 | 4.51 ± 0.23 | 8.36 ± 1.32 | 4.55 ± 0.16 | 5.03 ± 1.94 |
Macrophage | 4.16 ± 0.57 | 11.14 ± 4.08 | 8.91 ± 4.93 | 7.06 ± 3.92 | 3.86 ± 1.07 | 6.91 ± 1.96 | 3.91 ± 0.74 | 4.03 ± 0.43 |
Lymphocyte | 0.08 ± 0.01 | 12.63 ± 2.49 | 1.76 ± 0.67 | 1.33 ± 0.67 | 1.32 ± 0.54 | 2.43 ± 0.43 | 1.44 ± 0.32 | 0.56 ± 0.21 |
PMN | 0.03 ± 0.01 | 4.5 ± 0.97 | 0.41 ± 0.07 | 0.87 ± 0.32 | 0.67 ± 0.32 | 1.02 ± 0.22 | 0.67 ± 0.11 | 0.41 ± 0.13 |
C. Number of (CD45+) cells in lung parenchyma before and after bleomycin treatment | ||||||||
LP (d7) | Â | Â | Â | Â | Â | Â | Â | Â |
10 5 /m1 | WS | WB | NOXS | NOXB | DKOS | DKOB | ||
Total cells | 7.27 ± 0.07 | 38.3 ± 4.04 | 8.86 ± 0.08 | 54.19* ± 2.6 | 6.85 ± 0.27 | 9.56 ± 0.65 | ||
Macrophage | 6.16 ± 0.57 | 22.14 ± 4.08 | 7.13 ± 2.43 | 31.38* ± 11.32 | 5.41 ± 1.43 | 6.36 ± 2.71 | ||
Lymphocyte | 1.08 ± 0.01 | 9.63 ± 2.49 | 0.97 ± 0.12 | 21.41* ± 4.93 | 0.93 ± 0.21 | 2.47 ± 0.67 | ||
PMN | 0.03 ± 0.01 | 7.5 ± 0.97 | 0.72 ± 0.04 | 1.34 ± 0.15 | 0.51 ± 0.03 | 0.73 ± 0.33 | ||
% | WS | WB | NOXS | NOXB | DKOS | DKOB | ||
Macrophage | 84.73 ± 1.86 | 57.80 ± 11.75 | 80.47 ± 12.96 | 57.96 ± 2.98 | 78.97 ± 3.76 | 66.52 ± 5.98 | ||
Lymphocyte | 14.85 ± 2.84 | 25.14 ± 4.96 | 10.94 ± 1.95 | 39.50 ± 3.67 | 13.57 ± 3.98 | 25.83 ± 8.43 | ||
PMN | 0.41 ± 0.04 | 19.58 ± 6.73 | 8.12 ± 2.07 | 2.47 ± 1.09 | 7.44 ± 1.97 | 7.63 ± 2.06 | ||
D. Number of CD45- cells in lunb parenchyma counterstained with alveolar epithelial cell markers before and after bleomycin treatment | ||||||||
 | saline | bleomycin | ||||||
WT | Day 21 | Day 7 | Day 14 | Day 21 | ||||
AEI | 95.7 ± 4.87 | 79.47 ± 2.86 | 67.43 ± 1.76 | 58.41 ± 4.83 | ||||
AEII | 4.3 ± 1.76 | 9.41 ± 1.86 | 8.66 ± 1.07 | 5.96 ± 1.12 | ||||
NOX-/- | Â | Â | Â | Â | Â | Â | Â | Â |
AEI | 95.7 ± 3.87 | 66.21 ± | 58.23 ± 2.34 | 56.14 ± 3.97 | ||||
AEII | 4.3 ± 1.12 | 4.89 ± | 5.43 ± 1.06 | 5.77 ± 0.56 | ||||
DKO | Â | Â | Â | Â | Â | Â | Â | Â |
AEI | 95.7 ± 4.16 | 96.23 ± 4.75 | 96.44 ± 11.23 | 97.41 ± 3.87 | ||||
AEII | 4.3 ± 0.56 | 4.5 ± 0.09 | 4.86 ± 1.94 | 4.96 ± 1.87 |